Roche Holding Ltd

ROG

Equity

ISIN CH0012032048 / Valor 1203204

SIX Swiss Exchange (2024-09-18)

CHF 268.40+0.83%

Roche Holding Ltd
UMushroom community rating:

4.53 5 votes No rating yet

NegativeNeutralPositive

About company

Roche Holding Ltd is a global healthcare company known for being one of the largest biotech companies and a leading supplier of in-vitro diagnostics. The company is an innovator in various disease areas such as oncology, neurology, infectious diseases, and ophthalmology. Roche has established partnerships with forward-thinking organizations that share the belief in the power of cutting-edge science and technology to enhance human health.

Summarized from source with an LLMView SourceSector: Healthcare

Group Sales and Margin Trends

In the first quarter of 2023, Roche Holding Ltd reported group sales of CHF 58.7 billion, reflecting a slight decrease of 1% compared to the previous year. Despite the challenges posed by the COVID-19 pandemic, the company managed to maintain a strong performance across its various business segments.

Core Operating Profit

Roche Holding Ltd's core operating profit for Q1 2023 stood at CHF 58.7 billion, marking a 1% decline from the previous year. This slight decrease was attributed to the ongoing impact of the pandemic on certain business operations, although the company still demonstrated resilience in its financial performance.

Core Earnings per Share

For the first quarter of 2023, Roche Holding Ltd reported core earnings per share of CHF 18.57, which represents a 6% increase compared to the same period in the previous year. This growth in earnings per share highlights the company's ability to generate value for its shareholders despite external challenges.

Operating Free Cash Flow

Roche Holding Ltd achieved an operating free cash flow of CHF 15.8 billion in Q1 2023, reflecting a 4% increase from the previous year. This positive cash flow performance underscores the company's strong operational efficiency and effective cash management strategies.

Dividend Increases

In line with its commitment to returning value to shareholders, Roche Holding Ltd announced a dividend increase for the 37th consecutive year in Q1 2023. The gross dividend for Roche was raised by 2%, further solidifying the company's reputation for consistent and reliable dividend payouts.

Summarized from source with an LLMView Source

Key figures

4.05%1Y

-21.7%3Y

-4.67%5Y

Performance

20.1%1Y

19.2%3Y

20.6%5Y

Volatility

222090 M

Market cap (USD)

668,798

Daily traded volume (Shares)

269.3 / 266

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.53

5 votes

Performance:

3.64

Innovation:

4.07

Society:

4.21

Nature:

3.64

smail alijagic

Switzerland, 03 Jul 2024

Gutes Unternehmen, leidet aktuell unter den abgelaufenen Patenten und schlecht gefüllter Pipeline

Vladimir Jovicic

Switzerland, 06 Dec 2023

You can take your beetroot juice, your ginger shots, your pro/prebiotics, your daily exercise, your morning sunlight and vitamin D, your magnesium glycinate (better for assimilation apparently), your meditation before 8h sleep, your portfolio would still need a healthy dose of good ol' Roche.